Biotech
Nura Bio
Nura Bio raises $68M Series A at $300M valuation
$68M
Total Raised
Series A
Latest Round
2021
Founded
70+
Employees
South San Francisco, CA
1 min read
Quick Facts
Valuation
$300M
Latest Round Size
$68M
Latest Round Date
October 2024
Nura Bio: Series A Funding Round
Nura Bio has successfully raised $68M in Series A funding, reaching a valuation of $300M.
Company Overview
Biopharmaceutical company developing therapies for neurological diseases
Funding Details
The Series A round was led by Atlas Venture, with participation from Deerfield Management.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2021
- Employees: 70+
- Category: Biotech
Investment
Nura Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Atlas Venture: Verified investor in Series A
- Deerfield Management: Verified investor in Series A
Key Investors
Atlas Venture
Lead Investor
Verified investor in Series A
Deerfield Management
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M